Temporal Trends in Antineoplastic Agent-associated Interstitial Lung Disease Involving Immune Checkpoint Inhibitors in the JADER Database

CONCLUSION: The recent increase in antineoplastic agent-associated DIILD may primarily be driven by the expanding use of ICIs, particularly ICI in combination with chemotherapy. Because DIILD tends to occur in the early phase of treatment, strict monitoring is warranted during the initial therapy period.